COMP <GO>
RKLB vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Rocket Lab Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: RKLB 4
— TMO 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RKLB
LAST: $54.73 (-7.39%) • MKT CAP: $37.10B
balance-sheet
26.00
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RKLB VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RKLB | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.40% | 41.00% | -6.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.10% | 9.30% | -15.40 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.87% | 2.40% | -3.27 | TMO | /fcf-yield <GO> |
| Operating Margin | -38.00% | 17.40% | -55.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | -32.90% | 15.10% | -48.00 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 38.00% | 3.90% | +34.10 | RKLB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 4.50 | +21.50 | RKLB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.70% | +0.70 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.0 | 59.1 | -19.19 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.94 | +0.21 | RKLB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 36.3x | -16.30 | RKLB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.10B | $262.22B | -$225.12B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RKLB REV | TMO REV | RKLB GROSS % | TMO GROSS % | RKLB FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $601.8M | $44.56B | 34.4% | 44.0% | -$321.8M | $6.29B |
| FY 2024 | $436.2M | $42.88B | 26.6% | 44.0% | -$116.0M | $7.27B |
| FY 2023 | $244.6M | $42.86B | 44.0% | 44.0% | -$109.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RKLB // BETA 1.15
TMO // BETA 0.94